

## Disclosures

### Personal Commercial (18)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Abbott Laboratories	Research/Research Grants ‡ Pilot Study	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Abbott Laboratories	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
AbbVie, Inc.	Data Safety Monitoring Board	Significant (>= \$5,000)	General Cardiology
Abiomed	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Bayer Healthcare Pharmaceuticals	Data Safety Monitoring Board	Modest (< \$5,000)	General Cardiology
CVRx	Data Safety Monitoring Board	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Eli Lilly and Company	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Imbria	Officer, Director, Trustee, or other Fiduciary Role	Significant (>= \$5,000)	Stable Ischemic Heart Disease
Jana Care	Officer, Director, Trustee, or other Fiduciary Role	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Janssen Pharmaceuticals, Inc	Research/Research Grants	Significant (>= \$5,000)	Prevention
Medtronic	Research/Research Grants	Modest (< \$5,000)	Valvular Heart Disease
Novartis	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Novo Nordisk Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Prevencio	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
Roche Diagnostics	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies General Cardiology
Siemens	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Takeda Pharmaceuticals North America, Inc	Data Safety Monitoring Board	Significant (>= \$5,000)	General Cardiology

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

## Agreement

Certified Education Attestation | Signed on 8/23/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

## **Confidentiality, Disclosure and Assignment Agreement** | Signed on 8/23/2023

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>*

## **Embargo** | Signed on 8/23/2023

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

## **On-Going Obligation Agreement** | Signed on 8/23/2023

---

### **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.